Home > Views > Blogs > Tech Observer > Questcor: From Orphan Drug To Orphan Stock?
EMAIL
PRINT
RSS
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Letters are not case-sensitive, disregard spaces.
captcha image
Try a New One
This helps us prevent automated registrations and spamming.

Main
Esquire, E-Ink: Future of Print?   Tell Us You're Healthy, Steve Jobs
Jul 23 2008 12:48PM EDT

Questcor: From Orphan Drug To Orphan Stock?

Blaise Zerega can't fathom an 1,800% price hike.  Russ Mitchell's examination yesterday of why Questcor Pharmaceuticals raised the price of a drug used to treat infantile epilepsy from $1,600 per vial to $23,000 per vial helps set the stage for Congressional hearings tomorrow. But in the meanwhile, the company's share price is already taking a hit, down 9% to $4.57 as of this posting. What if it QCOR shares eventually fell 1,800%? Instant karma, anyone?

See more in

Loading...

Add Your Comment

Required fields are marked with an asterisk (*)
Add a comment

Archive

Previous
Aug
2008
Next


Also in Portfolio.com
Most Read
Most Emailed
Recently Commented